Rapport Therapeutics (RAPP) Equity Ratio (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Equity Ratio data on file, last reported at 0.95 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.95, changed 0.13% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.95 (changed 0.13% YoY), and the FY2025 annual result was 0.95, down 2.48% from the prior year.
• Equity Ratio steadied at 0.95 in Q1 2026 per RAPP's latest filing, from 0.95 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.98 in Q3 2024 and troughed at 0.16 in Q4 2023.
• A 4-year average of 0.83 and a median of 0.95 in 2026 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio soared 688.01% in 2024, then retreated 5.18% in 2025.
• A 4-year view of Equity Ratio shows it stood at 0.16 in 2023, then soared by 688.01% to 0.97 in 2024, then decreased by 2.48% to 0.95 in 2025, then increased by 0.19% to 0.95 in 2026.
• Business Quant data shows RAPP's Equity Ratio at 0.95 in Q1 2026, 0.95 in Q4 2025, and 0.96 in Q3 2025.